vs

Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $88.2M, roughly 1.7× FIRST MID BANCSHARES, INC.). FIRST MID BANCSHARES, INC. runs the higher net margin — 26.8% vs -5.5%, a 32.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 3.4%). FIRST MID BANCSHARES, INC. produced more free cash flow last quarter ($124.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 5.0%).

First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

FMBH vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.7× larger
TARS
$151.7M
$88.2M
FMBH
Growing faster (revenue YoY)
TARS
TARS
+125.0% gap
TARS
128.4%
3.4%
FMBH
Higher net margin
FMBH
FMBH
32.4% more per $
FMBH
26.8%
-5.5%
TARS
More free cash flow
FMBH
FMBH
$111.1M more FCF
FMBH
$124.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
5.0%
FMBH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FMBH
FMBH
TARS
TARS
Revenue
$88.2M
$151.7M
Net Profit
$23.7M
$-8.4M
Gross Margin
Operating Margin
34.0%
-5.3%
Net Margin
26.8%
-5.5%
Revenue YoY
3.4%
128.4%
Net Profit YoY
23.5%
63.8%
EPS (diluted)
$0.98
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FMBH
FMBH
TARS
TARS
Q4 25
$88.2M
$151.7M
Q3 25
$89.3M
$118.7M
Q2 25
$87.5M
$102.7M
Q1 25
$84.3M
$78.3M
Q4 24
$85.3M
$66.4M
Q3 24
$80.6M
$48.1M
Q2 24
$79.2M
$40.8M
Q1 24
$79.9M
$27.6M
Net Profit
FMBH
FMBH
TARS
TARS
Q4 25
$23.7M
$-8.4M
Q3 25
$22.5M
$-12.6M
Q2 25
$23.4M
$-20.3M
Q1 25
$22.2M
$-25.1M
Q4 24
$19.2M
$-23.1M
Q3 24
$19.5M
$-23.4M
Q2 24
$19.7M
$-33.3M
Q1 24
$20.5M
$-35.7M
Operating Margin
FMBH
FMBH
TARS
TARS
Q4 25
34.0%
-5.3%
Q3 25
32.2%
-12.2%
Q2 25
34.4%
-21.6%
Q1 25
33.4%
-33.5%
Q4 24
29.7%
-36.8%
Q3 24
31.5%
-52.3%
Q2 24
33.7%
-81.6%
Q1 24
33.7%
-136.5%
Net Margin
FMBH
FMBH
TARS
TARS
Q4 25
26.8%
-5.5%
Q3 25
25.2%
-10.6%
Q2 25
26.8%
-19.8%
Q1 25
26.3%
-32.1%
Q4 24
22.5%
-34.8%
Q3 24
24.2%
-48.7%
Q2 24
24.9%
-81.6%
Q1 24
25.6%
-129.4%
EPS (diluted)
FMBH
FMBH
TARS
TARS
Q4 25
$0.98
$-0.17
Q3 25
$0.94
$-0.30
Q2 25
$0.98
$-0.48
Q1 25
$0.93
$-0.64
Q4 24
$0.81
$-0.57
Q3 24
$0.81
$-0.61
Q2 24
$0.82
$-0.88
Q1 24
$0.86
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FMBH
FMBH
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$354.5M
$72.4M
Stockholders' EquityBook value
$958.7M
$343.4M
Total Assets
$8.0B
$562.2M
Debt / EquityLower = less leverage
0.37×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FMBH
FMBH
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
FMBH
FMBH
TARS
TARS
Q4 25
$354.5M
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
FMBH
FMBH
TARS
TARS
Q4 25
$958.7M
$343.4M
Q3 25
$932.2M
$335.1M
Q2 25
$894.1M
$332.6M
Q1 25
$870.9M
$342.5M
Q4 24
$846.4M
$224.5M
Q3 24
$858.5M
$237.5M
Q2 24
$813.6M
$252.2M
Q1 24
$798.0M
$275.2M
Total Assets
FMBH
FMBH
TARS
TARS
Q4 25
$8.0B
$562.2M
Q3 25
$7.8B
$534.6M
Q2 25
$7.7B
$495.0M
Q1 25
$7.6B
$500.8M
Q4 24
$7.5B
$377.0M
Q3 24
$7.6B
$376.3M
Q2 24
$7.6B
$376.8M
Q1 24
$7.7B
$349.3M
Debt / Equity
FMBH
FMBH
TARS
TARS
Q4 25
0.37×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FMBH
FMBH
TARS
TARS
Operating Cash FlowLast quarter
$130.9M
$19.3M
Free Cash FlowOCF − Capex
$124.0M
$13.0M
FCF MarginFCF / Revenue
140.6%
8.6%
Capex IntensityCapex / Revenue
7.8%
4.2%
Cash ConversionOCF / Net Profit
5.53×
TTM Free Cash FlowTrailing 4 quarters
$207.9M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FMBH
FMBH
TARS
TARS
Q4 25
$130.9M
$19.3M
Q3 25
$33.0M
$18.3M
Q2 25
$7.7M
$-29.4M
Q1 25
$47.9M
$-20.7M
Q4 24
$124.4M
$-22.2M
Q3 24
$33.1M
$-8.7M
Q2 24
$24.0M
$-14.4M
Q1 24
$29.0M
$-37.8M
Free Cash Flow
FMBH
FMBH
TARS
TARS
Q4 25
$124.0M
$13.0M
Q3 25
$31.9M
$16.3M
Q2 25
$6.0M
$-30.4M
Q1 25
$46.0M
$-21.2M
Q4 24
$119.5M
$-22.3M
Q3 24
$32.0M
$-8.9M
Q2 24
$22.9M
$-15.4M
Q1 24
$27.6M
$-38.0M
FCF Margin
FMBH
FMBH
TARS
TARS
Q4 25
140.6%
8.6%
Q3 25
35.8%
13.8%
Q2 25
6.8%
-29.6%
Q1 25
54.5%
-27.1%
Q4 24
140.0%
-33.5%
Q3 24
39.7%
-18.6%
Q2 24
28.9%
-37.8%
Q1 24
34.5%
-137.5%
Capex Intensity
FMBH
FMBH
TARS
TARS
Q4 25
7.8%
4.2%
Q3 25
1.2%
1.6%
Q2 25
2.0%
1.0%
Q1 25
2.3%
0.8%
Q4 24
5.8%
0.1%
Q3 24
1.4%
0.6%
Q2 24
1.4%
2.5%
Q1 24
1.9%
0.6%
Cash Conversion
FMBH
FMBH
TARS
TARS
Q4 25
5.53×
Q3 25
1.47×
Q2 25
0.33×
Q1 25
2.16×
Q4 24
6.49×
Q3 24
1.70×
Q2 24
1.21×
Q1 24
1.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons